Advertisement

Corrigendum Open Access | 10.1172/JCI196275

Corrigendum to Targeting apoptotic pathways for cancer therapy

Xiaobing Tian, Praveen R. Srinivasan, Vida Tajiknia, Ashley F. Sanchez Sevilla Uruchurtu, Attila A. Seyhan, Benedito A. Carneiro, Arielle De La Cruz, Maximilian Pinho-Schwermann, Andrew George, Shuai Zhao, Jillian Strandberg, Francesca Di Cristofano, Shengliang Zhang, Lanlan Zhou, Alexander G. Raufi, Arunasalam Navaraj, Yiqun Zhang, Nataliia Verovkina, Maryam Ghandali, Dinara Ryspayeva, and Wafik S. El-Deiry

Find articles by Tian, X. in: PubMed | Google Scholar

Find articles by Srinivasan, P. in: PubMed | Google Scholar

Find articles by Tajiknia, V. in: PubMed | Google Scholar

Find articles by Sanchez Sevilla Uruchurtu, A. in: PubMed | Google Scholar

Find articles by Seyhan, A. in: PubMed | Google Scholar |

Find articles by Carneiro, B. in: PubMed | Google Scholar

Find articles by De La Cruz, A. in: PubMed | Google Scholar

Find articles by Pinho-Schwermann, M. in: PubMed | Google Scholar

Find articles by George, A. in: PubMed | Google Scholar

Find articles by Zhao, S. in: PubMed | Google Scholar

Find articles by Strandberg, J. in: PubMed | Google Scholar

Find articles by Di Cristofano, F. in: PubMed | Google Scholar

Find articles by Zhang, S. in: PubMed | Google Scholar

Find articles by Zhou, L. in: PubMed | Google Scholar

Find articles by Raufi, A. in: PubMed | Google Scholar

Find articles by Navaraj, A. in: PubMed | Google Scholar

Find articles by Zhang, Y. in: PubMed | Google Scholar

Find articles by Verovkina, N. in: PubMed | Google Scholar

Find articles by Ghandali, M. in: PubMed | Google Scholar

Find articles by Ryspayeva, D. in: PubMed | Google Scholar

Find articles by El-Deiry, W. in: PubMed | Google Scholar |

Published July 15, 2025 - More info

Published in Volume 135, Issue 14 on July 15, 2025
J Clin Invest. 2025;135(14):e196275. https://doi.org/10.1172/JCI196275.
© 2025 Tian et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published July 15, 2025 - Version history
View PDF

Related article:

Targeting apoptotic pathways for cancer therapy
Xiaobing Tian, … , Dinara Ryspayeva, Wafik S. El-Deiry
Xiaobing Tian, … , Dinara Ryspayeva, Wafik S. El-Deiry
Review

Targeting apoptotic pathways for cancer therapy

Abstract

Apoptosis is a form of programmed cell death that is mediated by intrinsic and extrinsic pathways. Dysregulation of and resistance to cell death are hallmarks of cancer. For over three decades, the development of therapies to promote treatment of cancer by inducing various cell death modalities, including apoptosis, has been a main goal of clinical oncology. Apoptosis pathways also interact with other signaling mechanisms, such as the p53 signaling pathway and the integrated stress response (ISR) pathway. In addition to agents directly targeting the intrinsic and extrinsic pathway components, anticancer drugs that target the p53 and ISR signaling pathways are actively being developed. In this Review, we discuss selected and promising anticancer therapies in various stages of development, including drug targets, mechanisms, and resistance to related treatments, focusing especially on B cell lymphoma 2 (BCL-2) inhibitors, TRAIL analogues, DR5 antibodies, and strategies that target p53, mutant p53, and the ISR.

Authors

Xiaobing Tian, Praveen R. Srinivasan, Vida Tajiknia, Ashley F. Sanchez Sevilla Uruchurtu, Attila A. Seyhan, Benedito A. Carneiro, Arielle De La Cruz, Maximilian Pinho-Schwermann, Andrew George, Shuai Zhao, Jillian Strandberg, Francesca Di Cristofano, Shengliang Zhang, Lanlan Zhou, Alexander G. Raufi, Arunasalam Navaraj, Yiqun Zhang, Nataliia Verovkina, Maryam Ghandali, Dinara Ryspayeva, Wafik S. El-Deiry

×

Original citation: J Clin Invest. 2024;134(14):e179570. https://doi.org/10.1172/JCI179570

Citation for this corrigendum: J Clin Invest. 2025;135(14):e196275. https://doi.org/10.1172/JCI196275

Following publication of this Review, the Editors became aware that portions of the text overlapped with text in prior publications by others (1–7) and by some of the Review authors (8, 9). To meet the originality requirements of the JCI, the authors have rewritten those portions of the review. The HTML and PDF versions have been updated online. In addition, the Journal has published an online version of the original article marking the edited text (Supplemental File, Redaction).

The authors regret the errors.

Supplemental material

View Supplemental data

Footnotes

See the related article at Targeting apoptotic pathways for cancer therapy.

References
  1. Gieffers C, et al. APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptors. Mol Cancer Ther. 2013;12(12):2735–2747.
    View this article via: CrossRef PubMed Google Scholar
  2. Phillips DC, et al. Hexavalent TRAIL fusion protein eftozanermin alfa optimally clusters apoptosis-inducing TRAIL receptors to induce on-target antitumor activity in solid tumors. Cancer Res. 2021;81(12):3402–3414.
    View this article via: CrossRef PubMed Google Scholar
  3. Papadopoulos KP, et al. Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor. Cancer Chemother Pharmacol. 2015;75(5):887–895.
    View this article via: CrossRef PubMed Google Scholar
  4. Fang DD, et al. MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models. Cell Death Discov. 2021;7(1):90.
    View this article via: CrossRef PubMed Google Scholar
  5. Guiley KZ, Shokat KM. A small molecule reacts with the p53 somatic mutant Y220C to rescue wild-type thermal stability. Cancer Discov. 2023;13(1):56–69.
    View this article via: CrossRef PubMed Google Scholar
  6. Pakos-Zebrucka K, et al. The integrated stress response. EMBO Rep. 2016;17(10):1374–1395.
    View this article via: CrossRef PubMed Google Scholar
  7. Bonner ER, et al. Mechanisms of impridones in targeting mitochondrial metabolism in cancer cells. Neuro Oncol. 2021;23(4):542–556.
    View this article via: CrossRef PubMed Google Scholar
  8. Di Cristofano F, et al. Therapeutic targeting of TRAIL death receptors. Biochem Soc Trans. 2023;51(1):57–70.
    View this article via: CrossRef PubMed Google Scholar
  9. Tian X, et al. P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9. Neoplasia. 2021;23(3):304–325.
    View this article via: PubMed CrossRef Google Scholar
Version history
  • Version 1 (July 15, 2025): Electronic publication
Advertisement
Advertisement